ArticleJournal of acquired immune deficiency syndromes (1999)2025
Brief Report: Undetectable HIV-1 Viral Load Among Virally Suppressed People Living With HIV: Implications for Undetectable Equals Untransmittable (U=U) in Resource-Limited Settings Using Dried Spot Testing.
Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
backgroundThe Undetectable=Untransmittable (U=U) campaign, grounded in strong scientific evidence, affirms that people living with HIV (PLHIV) with an undetectable viral load (VL), defined as ≤50 copies per milliliter (c/mL) or <200 c/mL of HIV RNA, do not transmit HIV to sexual partners. In resource-limited settings, VL is commonly measured using dried blood spot (DBS) testing, which has a higher limit of detection (550-1000 c/mL). We report the proportion of PLHIV with VL <1000 c/mL who also had VL <200 c/mL and ≤50 c/mL to inform interpretation of DBS VL results under U=U.
methodsWe analyzed data from 13 cross-sectional nationally representative surveys (2015-2019), including PLHIV aged 15-59 years receiving antiretroviral therapy (ART) with valid plasma VL results. We estimated the proportion of participants with VL <200 c/mL and ≤50 c/mL among those with VL <1000 c/mL, overall and among those on ART ≥12 months using survey weights.
resultsAmong 16,533 PLHIV across 13 countries, 87.3% had VL <1000 c/mL. For PLHIV with VL <1000 c/mL, 95.4% had VL <200 c/mL and 84.9% had VL ≤50 c/mL. Among those on ART ≥12 months, 96.6% had VL <200 c/mL, and 87.4% had VL ≤50 c/mL.
conclusionMost PLHIV with VL <1000 c/mL had a VL <200 c/mL and ≤50 c/mL, indicating no risk of sexual HIV transmission. Our findings provide evidence that in settings relying on DBS VL testing, most PLHIV with VL <1000 c/mL likely fall below 200 c/mL or are undetectable based on the assay's lower limit of detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.